Genetron (NYSE:GTH) Trading Up 10.1%

Genetron Holdings Limited (NYSE:GTH) was up 10.1% during trading on Thursday . The company traded as high as $14.00 and last traded at $14.00. Approximately 619,097 shares traded hands during mid-day trading, an increase of 98% from the average daily volume of 313,073 shares. The stock had previously closed at $12.72.

Separately, Canaccord Genuity reissued a “buy” rating and issued a $19.00 price objective on shares of Genetron in a research note on Wednesday, September 30th.

The firm has a 50 day moving average price of $12.89.

Genetron (NYSE:GTH) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $16.49 million for the quarter.

Several hedge funds have recently made changes to their positions in the company. Platinum Investment Management Ltd. raised its holdings in Genetron by 68.8% during the 3rd quarter. Platinum Investment Management Ltd. now owns 375,359 shares of the company’s stock worth $4,482,000 after buying an additional 153,045 shares during the period. Champlain Investment Partners LLC lifted its holdings in Genetron by 61.8% in the 3rd quarter. Champlain Investment Partners LLC now owns 40,445 shares of the company’s stock worth $483,000 after purchasing an additional 15,445 shares during the last quarter. Jennison Associates LLC lifted its holdings in Genetron by 20.5% in the 3rd quarter. Jennison Associates LLC now owns 910,427 shares of the company’s stock worth $10,870,000 after purchasing an additional 155,060 shares during the last quarter. Federated Hermes Inc. lifted its holdings in Genetron by 20.0% in the 3rd quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $717,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Yong Rong HK Asset Management Ltd lifted its holdings in Genetron by 108.3% in the 3rd quarter. Yong Rong HK Asset Management Ltd now owns 250,000 shares of the company’s stock worth $2,985,000 after purchasing an additional 130,000 shares during the last quarter.

About Genetron (NYSE:GTH)

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for Genetron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetron and related companies with MarketBeat.com's FREE daily email newsletter.